News for Agios Pharmaceuticals, Inc. (0HB0.L)

Agios Pharmaceuticals (AGIO) has revealed significant findings on its PK activators, mitapivat and tebapivat, at the 30th European Hematology Association Congre

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. ( AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pi

Agios Pharmaceuticals (AGIO) to present at the 2025 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 21, 2025, at

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. ( AGIO), a leader in cellular metabolism and PK activation pioneering therapies

**media[620230]**

\nAgios Pharmaceuticals Inc's innovative approach to cellular metabolism positions it at the forefront of rare disease treatment.Despite a strong product pipelin

**media[612617]**

The following slide deck was published by Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsChris Taylor – Vice President-Investor...

We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode.  In this article, we are going to take a look at where Agios Pharmaceuticals, Inc.

**media[558517]**

**media[556678]**

Summary Agios Pharmaceuticals Inc (AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, announced on March 4, 2025, that its ma

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. ( AGIO), a leader in cellular metabolism and PK activation pioneering therapi

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where Agios Pharmaceuticals, Inc.

Operator: Good morning, and welcome to Agios' Fourth Quarter 2024 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.

On December 31, 2024, BB Biotech AG executed a significant transaction involving Agios Pharmaceuticals Inc. The firm reduced its holdings by 515,642 shares at a

Insightful Analysis of Jefferies Group (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Jefferies Group (Trades, Portfolio) recently submitted its 13F fili

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsBrian Goff - CEOSarah Gheuens -...